US estrogen patch shortage exposes systemic fragility in pharmaceutical supply chains and gendered healthcare inequities

Indigenous and traditional medicine systems offer hormone-balancing alternatives like black cohosh, chasteberry, and adaptogenic herbs, which are often excluded from Western pharmaceutical supply chains due to regulatory biases. These systems also emphasize community-based care models that could mitigate the isolation and desperation experienced during shortages. However, their integration into mainstream healthcare is hindered by colonial legacies that devalue non-Western knowledge and by patent laws that favor synthetic pharmaceuticals. The exclusion of these perspectives perpetuates a monoculture of medical solutions that is vulnerable to systemic collapse.

The current shortage echoes historical patterns of hormone therapy regulation, such as the 2002 Women’s Health Initiative (WHI) study, which linked HRT to increased cancer risks and led to a dramatic decline in prescriptions. This shift was driven by pharmaceutical industry lobbying and media amplification of risks, despite later studies showing that the WHI’s findings were overgeneralized and that HRT benefits outweigh risks for many women. The FDA’s recent championing of off-label use for estrogen patches reflects a reactive policy cycle that fails to address structural causes of supply chain fragility, such as consolidation in hormone production.

Cross-culturally, hormone health is approached through diverse lenses: in Traditional Chinese Medicine (TCM), imbalances are treated with acupuncture and herbal formulas like Dang Gui (Angelica sinensis), which are now being studied for their estrogenic effects. In African diasporic traditions, remedies like vitex (chasteberry) and moringa are used to regulate menstrual cycles and menopausal symptoms, yet these are rarely integrated into Western treatment protocols. The Western biomedical model’s focus on synthetic hormones as the sole solution ignores these time-tested alternatives, which could reduce reliance on fragile supply chains. Integrating these systems could create resilience against future shortages.

Scientifically, the shortage stems from a combination of factors: monopolistic production by a few pharmaceutical companies (e.g., Pfizer, Novartis), just-in-time inventory models that prioritize efficiency over redundancy, and FDA policies that allow for expedited approvals without addressing supply chain vulnerabilities. Studies show that hormone production is highly concentrated, with 80% of global estrogen supply controlled by a handful of firms, making the system prone to disruption. The FDA’s recent guidance on off-label use of estrogen patches is a stopgap measure that does not address the root causes of fragility in pharmaceutical manufacturing.

Artistically and spiritually, the crisis reflects a broader cultural disconnect between the body and synthetic interventions, as seen in movements like menstrual activism and body-positivity art that challenge the medicalization of natural processes. Indigenous and feminist artists have long used their work to critique pharmaceutical hegemony, such as Judy Chicago’s *The Dinner Party*, which celebrates women’s bodies and traditional healing practices. Spiritual traditions, from Ayurveda to African spiritual systems, frame hormonal balance as part of a holistic relationship with the earth and community, offering metaphors for systemic healing beyond market-based solutions.

Future modelling suggests that without systemic reforms, pharmaceutical supply chains will remain vulnerable to shocks, with estrogen shortages becoming a recurring crisis as climate change disrupts agricultural inputs for synthetic hormone production. Scenario planning indicates that decentralized, community-based production of hormone alternatives (e.g., phytoestrogens) could reduce dependency on global supply chains, while blockchain-enabled tracking of pharmaceutical distribution could prevent hoarding and price gouging. Policymakers must also model the long-term health impacts of prolonged hormone deprivation, particularly for transgender and non-binary individuals who rely on consistent access to HRT.

Marginalized voices—including transgender women, Black and Indigenous women, low-income patients, and rural communities—are disproportionately affected by the shortage due to systemic barriers like cost, provider bias, and geographic access to healthcare. Transgender individuals, for example, face additional hurdles in accessing estrogen due to insurance denials and discriminatory policies, exacerbating mental health crises during shortages. Indigenous women often lack access to culturally competent care and may turn to unregulated sources of hormones due to historical mistrust of Western medicine. The framing of this crisis as a generic 'supply issue' erases these intersecting vulnerabilities and the need for targeted policy interventions.